Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
20.80
-0.42 (-1.98%)
At close: Jan 17, 2025, 4:00 PM
21.42
+0.62 (2.98%)
After-hours: Jan 17, 2025, 5:44 PM EST
Genmab Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Genmab stock have an average target of 43, with a low estimate of 31 and a high estimate of 50. The average target predicts an increase of 106.73% from the current stock price of 20.80.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Genmab stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 | Strong Buy | Maintains | $50 | +140.38% | Jan 8, 2025 |
| BMO Capital | BMO Capital | Buy Reiterates $46 → $48 | Buy | Reiterates | $46 → $48 | +130.77% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +140.38% | Oct 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +140.38% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +140.38% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
21.75B
from 16.47B
Increased by 32.03%
Revenue Next Year
25.44B
from 21.75B
Increased by 16.97%
EPS This Year
86.24
from 66.02
Increased by 30.63%
EPS Next Year
98.92
from 86.24
Increased by 14.70%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 22.9B | 27.6B | 32.9B | |||
| Avg | 21.8B | 25.4B | 29.2B | |||
| Low | 19.4B | 21.9B | 24.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 38.7% | 26.9% | 29.4% | |||
| Avg | 32.0% | 17.0% | 14.7% | |||
| Low | 18.0% | 0.7% | -5.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 98.10 | 141.03 | 187.12 | |||
| Avg | 86.24 | 98.92 | 124.57 | |||
| Low | 75.14 | 71.58 | 86.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 48.6% | 63.5% | 89.2% | |||
| Avg | 30.6% | 14.7% | 25.9% | |||
| Low | 13.8% | -17.0% | -12.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.